Cortometrajes de vídeo

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

Iron chelation therapy (ICT) in MDS is used to manage iron overload from frequent blood transfusions. It involves identifying patients who would benefit most, monitoring iron levels, and managing side effects of chelators

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.

Metastatic Triple Negative Breast Cancer is still an unmet medical need.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Immunotherapy has redefined the treatment of Triple Negative Breast Cancer.